Viridian Therapeutics company info

What does Viridian Therapeutics do?
Viridian Therapeutics (NASDAQ:VRDN) focuses on advancing innovative treatments for patients battling serious diseases, with a significant emphasis on thyroid eye disease (TED) and other autoimmune and fibrotic diseases. The company operates with the mission to transform the lives of those afflicted by these conditions through groundbreaking therapies and treatments. By diving deep into research and development, Viridian aims to address the unmet medical needs of patients worldwide. Its projects range from early-stage investigation to near-market therapies, highlighting a commitment to scientific excellence and patient care. Objectives of Viridian include spearheading the development of novel treatments, ensuring accessibility to these innovations, and continuously exploring new therapeutic areas to expand their impact on healthcare.
Viridian Therapeutics company media
Company Snapshot

Is Viridian Therapeutics a public or private company?

key
Ownership
Public

How many people does Viridian Therapeutics employ?

people
Employees
118

What sector is Viridian Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Viridian Therapeutics?

location pin
Head Office
Massachusetts, United States

What year was Viridian Therapeutics founded?

founded flag
Year Founded
2010
What does Viridian Therapeutics specialise in?
/Cancer Therapeutics /Biotechnology Company /RNA Interference /Drug Development /Clinical Trials /Healthcare Services

What are the products and/or services of Viridian Therapeutics?

Overview of Viridian Therapeutics offerings
VRDN-001, an anti-IGF-1R monoclonal antibody targeting thyroid eye disease.
VRDN-002, a next-generation anti-IGF-1R antibody with a half-life extension technology.
VRDN-003, a preclinical program focused on immune-mediated conditions.
VRDN-004, a development program aimed at optimizing antibody delivery methods.
A portfolio of bispecific antibodies designed for enhanced therapeutic targeting.
Strategic collaborations to expand their research and development in immunology and oncology.

Who is in the executive team of Viridian Therapeutics?

Viridian Therapeutics leadership team
  • Mr. Stephen F. Mahoney J.D., MBA
    Mr. Stephen F. Mahoney J.D., MBA
    CEO, President & Director
  • Dr. Eric N. Olson Ph.D.
    Dr. Eric N. Olson Ph.D.
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow M.D., Ph.D.
    Dr. Michael R. Bristow M.D., Ph.D.
    Co-Founder & Member of the Scientific Advisory Board
  • Dr. Marvin H. Caruthers Ph.D.
    Dr. Marvin H. Caruthers Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Mr. Vahe  Bedian Ph.D.
    Mr. Vahe Bedian Ph.D.
    Co-Founder & Scientific Advisor
  • Mr. Seth  Harmon
    Mr. Seth Harmon
    Senior VP of Finance and Accounting, Principal Financial & Accounting Officer
  • Mr. Thomas W. Beetham J.D., MBA
    Mr. Thomas W. Beetham J.D., MBA
    Chief Operating Officer
  • Ms. Jennifer  Tousignant J.D.
    Ms. Jennifer Tousignant J.D.
    Chief Legal Officer